Premium
Diffuse large B‐cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate
Author(s) -
Nakashima C.,
Tanioka M.,
Takahashi K.,
Miyachi Y.
Publication year - 2008
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2007.02683.x
Subject(s) - rheumatoid arthritis , medicine , dermatology , infliximab , family medicine , tumor necrosis factor alpha
Summary Infliximab is a tumour necrosis factor (TNF)‐α blocking drug classified as a biological response modifier. It has been suggested that the risk of malignancies, especially lymphomas, is increased in patients with rheumatoid arthritis (RA) treated with anti‐TNF‐α antibody therapy. We present a case of malignant lymphoma during the treatment of RA with infliximab and methotrexate.